On August 28, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Aurinia Pharmaceuticals, AUG 28, 2018, https://ir.auriniapharma.com/news/detail/122/aurinia-announces-participation-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018 [SID1234529090]). The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company’s business on Thursday, September 6 at 10:50am ET.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

On August 28, 2018 GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP.PA) reported the initiation of a combination trial of OXS-1550 and multi-billion dollar oncology drug, owned by a major Pharmaceutical Company (the Company) (Press release, GT Biopharma , AUG 28, 2018, View Source [SID1234539524]). This effort is headed by Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. Under this Material Transfer Agreement (MTA) announced on July 19, 2018 between GT Biopharma, Inc and the Company, Dr. Vallera has been supplied with a formulation of their this widely prescribed drug approved for use in several hematologic malignancies for preclinical studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Daniel Vallera said: "Based on our exciting preliminary in vitro experiments, the initial preclinical work suggests a much greater effect when OXS-1550 is given with this drug. We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor which is already an established chemotherapeutic agent. We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment."

Dr. Vallera is the lead researcher for GT Biopharma’s bispecific antibody drug conjugate (ADC) program, and the innovator of DT2219, also known as OXS-1550. OXS-1550 is a bispecific antibody drug conjugate which means it targets two antigens on cancer cells and contains a cytotoxic payload thereby increasing the probability it will kill the cancer cells. OXS-1550 targets cancer cells expressing the CD19 receptor and/or CD22 receptors which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploy its cytotoxic diphtheria toxin payload which inhibits protein synthesis and kills the cancer cells.

On August 28, 2018 VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 12:05 PM ET (Press release, VBI Vaccines, AUG 28, 2018, View Source [SID1234529430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at: www.vbivaccines.com/investors/events-presentations/. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

Event: 20th Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC
Date: Thursday, September 6, 2018
Time: 12:05 – 12:30 p.m. ET
Location: Louis XVI A, St. Regis New York Hotel in New York City
Webcast: View Source

On August 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional, reported that it is scheduled to attend the following investor conferences in September 2018 (Press release, Kiadis, AUG 28, 2018, View Source [SID1234529092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 8th Annual Biotech Symposium

September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK

Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease

September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA

KBC Securities 6th Biotech and Healthcare Conference

September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications

Tel. +31 611 096 298

[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile

Tel: +44 203 714 1787

[email protected]

On August 28, 2018 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported that Marty Duvall, chief executive officer, will participate in a panel discussion titled, "Chinese Capital Meets Western Innovation" on Tuesday, September 4, at 11:20 a.m. Eastern Standard Time, at the B. Riley FBR Annual Healthcare Conference (Press release, Tocagen, AUG 28, 2018, View Source;p=RssLanding&cat=news&id=2365149 [SID1234529155]). In addition, Mr. Duvall will present a corporate overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Wednesday, September 5, at 9:35 a.m. Eastern Standard Time, also in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast from the H.C. Wainwright conference and subsequent replay may be accessed by visiting the "Events & Presentations" page in the investors section of Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 30 days following the presentation.